Summary
The pharmaceutical company Novo Nordisk is facing a lawsuit after a woman named Marsha Ettinghoff, who was using their drug Ozempic, died from stomach paralysis. The lawsuit claims that the company did not properly warn users about the drug's risks, including severe gastrointestinal issues. Novo Nordisk denies these allegations and intends to defend against the claims.
Key Facts
- Marsha Ettinghoff, 76, died in August 2024 after using Ozempic, allegedly from stomach paralysis.
- Ozempic is approved by the FDA for type 2 diabetes and other health issues, but not for weight loss.
- The lawsuit claims Novo Nordisk failed to update warnings about serious gastrointestinal risks.
- Over 2,000 lawsuits related to this issue have been combined in Pennsylvania for pretrial proceedings.
- Novo Nordisk insists that Ozempic is safe when used according to its guidelines and denies the claims.
- The lawsuit calls for damages and a jury trial to address the alleged shortcomings in patient safety warnings.
